Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus responsible for coronavirus disease 2019 (COVID‐19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin‐converting enzyme 2 (ACE2), which facilitates SARS‐CoV‐2 host cell entry, may be impacted by...

詳細記述

保存先:
書誌詳細
出版年:J Clin Hypertens (Greenwich)
主要な著者: Cohen, Jordana B., Hanff, Thomas C., Corrales‐Medina, Vicente, William, Preethi, Renna, Nicolas, Rosado‐Santander, Nelson R., Rodriguez‐Mori, Juan E., Spaak, Jonas, Andrade‐Villanueva, Jaime, Chang, Tara I., Barbagelata, Alejandro, Alfonso, Carlos E., Bernales‐Salas, Eduardo, Coacalla, Johanna, Castro‐Callirgos, Carlos Augusto, Tupayachi‐Venero, Karen E., Medina, Carola, Valdivia, Renzo, Villavicencio, Mirko, Vasquez, Charles R., Harhay, Michael O., Chittams, Jesse, Sharkoski, Tiffany, Byrd, James Brian, Edmonston, Daniel L., Sweitzer, Nancy, Chirinos, Julio A.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Covid‐19
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722152/
https://ncbi.nlm.nih.gov/pubmed/32937008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.14011
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料